Truxima (rituximab) 500 mg concentrate for solution for infusion – Risk minimisation materials

This guide is intended to present important safety information including the risk of infections and progressive multifocal leukoencephalopathy associated with the use of Truxima in non-oncology diseases, and to provide important patient counselling information.

Patients should be advised of the importance of seeking medical attention immediately if they experience any of these symptoms after their treatment:

• Symptoms of an infection, for example fever, persistent cough, weight loss or listlessness

• Confusion, memory loss or problems thinking

• Loss of balance or a change in the way they walk or talk

• Decreased strength or weakness on one side of the body

• Blurred vision or loss of vision

The risk minimisation materials also include a Patient Alert Card which includes advice on what to do if a patient experiences adverse symptoms, and details of their treatment plan, and a Patient Information brochure.